Cargando…

1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)

BACKGROUND: PLG0206 is a novel engineered cationic antimicrobial peptide being evaluated for treatment of prosthetic joint infections. In this study, the activity of PLG0206 was evaluated by broth microdilution against 104 isolates of Staphylococcus epidermidis, 53 other coagulase-negative staphyloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, David, Steckbeck, Jonathan, Pillar, Chris, Murray, Bev, Huganfel, David, Shinabanger, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644086/
http://dx.doi.org/10.1093/ofid/ofab466.1264
_version_ 1784610004736671744
author Huang, David
Steckbeck, Jonathan
Pillar, Chris
Murray, Bev
Huganfel, David
Shinabanger, Dean
author_facet Huang, David
Steckbeck, Jonathan
Pillar, Chris
Murray, Bev
Huganfel, David
Shinabanger, Dean
author_sort Huang, David
collection PubMed
description BACKGROUND: PLG0206 is a novel engineered cationic antimicrobial peptide being evaluated for treatment of prosthetic joint infections. In this study, the activity of PLG0206 was evaluated by broth microdilution against 104 isolates of Staphylococcus epidermidis, 53 other coagulase-negative staphylococci (CoNS), 3 S. aureus, and 66 Gram-negative isolates consisting of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. METHODS: Imipenem, levofloxacin, tigecycline, linezolid, vancomycin, oxacillin, ceftazidime, colistin, and amikacin were tested as comparators. Testing was conducted in accordance with guidelines from the Clinical and Laboratory Standards Institute (CLSI; M7 and M100). Test organisms consisted of reference strains from the American Type Culture Collection, the Centers for Disease Control Antibiotic Reference Bank and clinical isolates from the Micromyx repository. The media employed for testing in the broth microdilution MIC assay for all organisms were cation-adjusted Mueller Hinton Broth and for PLG0206 only included RPMI-1640 medium supplemented with 0.002% P-80. RESULTS: Activity of PLG0206 in RPMI against CoNS, S. aureus, and resistant Gram-negative* pathogens are shown in Table. Activity of PLG0206 in RPMI against CoNS, S. aureus and resistant Gram-negative* pathogens [Image: see text] Activity of PLG0206 in RPMI against CoNS, S. aureus and resistant Gram-negative* pathogens CONCLUSION: PLG0206 was found to have potent antimicrobial activity when evaluated in RPMI against S. epidermidis, CoNS non-epidermidis, S. aureus, Enterobacterales, P. aeruginosa, and A. baumannii, including isolates with multi-drug resistance. DISCLOSURES: David Huang, MD, PhD, Peptilogics (Employee) Jonathan Steckbeck, PhD, Peptilogics (Employee) Chris Pillar, PhD, Micromyx (Employee) Bev Murray, BS, Micromyx (Employee) David Huganfel, BS, Micromyx (Employee) Dean Shinabanger, PhD, Micromyx (Employee)
format Online
Article
Text
id pubmed-8644086
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86440862021-12-06 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI) Huang, David Steckbeck, Jonathan Pillar, Chris Murray, Bev Huganfel, David Shinabanger, Dean Open Forum Infect Dis Poster Abstracts BACKGROUND: PLG0206 is a novel engineered cationic antimicrobial peptide being evaluated for treatment of prosthetic joint infections. In this study, the activity of PLG0206 was evaluated by broth microdilution against 104 isolates of Staphylococcus epidermidis, 53 other coagulase-negative staphylococci (CoNS), 3 S. aureus, and 66 Gram-negative isolates consisting of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. METHODS: Imipenem, levofloxacin, tigecycline, linezolid, vancomycin, oxacillin, ceftazidime, colistin, and amikacin were tested as comparators. Testing was conducted in accordance with guidelines from the Clinical and Laboratory Standards Institute (CLSI; M7 and M100). Test organisms consisted of reference strains from the American Type Culture Collection, the Centers for Disease Control Antibiotic Reference Bank and clinical isolates from the Micromyx repository. The media employed for testing in the broth microdilution MIC assay for all organisms were cation-adjusted Mueller Hinton Broth and for PLG0206 only included RPMI-1640 medium supplemented with 0.002% P-80. RESULTS: Activity of PLG0206 in RPMI against CoNS, S. aureus, and resistant Gram-negative* pathogens are shown in Table. Activity of PLG0206 in RPMI against CoNS, S. aureus and resistant Gram-negative* pathogens [Image: see text] Activity of PLG0206 in RPMI against CoNS, S. aureus and resistant Gram-negative* pathogens CONCLUSION: PLG0206 was found to have potent antimicrobial activity when evaluated in RPMI against S. epidermidis, CoNS non-epidermidis, S. aureus, Enterobacterales, P. aeruginosa, and A. baumannii, including isolates with multi-drug resistance. DISCLOSURES: David Huang, MD, PhD, Peptilogics (Employee) Jonathan Steckbeck, PhD, Peptilogics (Employee) Chris Pillar, PhD, Micromyx (Employee) Bev Murray, BS, Micromyx (Employee) David Huganfel, BS, Micromyx (Employee) Dean Shinabanger, PhD, Micromyx (Employee) Oxford University Press 2021-12-04 /pmc/articles/PMC8644086/ http://dx.doi.org/10.1093/ofid/ofab466.1264 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Huang, David
Steckbeck, Jonathan
Pillar, Chris
Murray, Bev
Huganfel, David
Shinabanger, Dean
1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title_full 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title_fullStr 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title_full_unstemmed 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title_short 1070. In vitro Activity of PLG0206 Against Isolates Commonly Found in Periprosthetic Joint Infections (PJI)
title_sort 1070. in vitro activity of plg0206 against isolates commonly found in periprosthetic joint infections (pji)
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644086/
http://dx.doi.org/10.1093/ofid/ofab466.1264
work_keys_str_mv AT huangdavid 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji
AT steckbeckjonathan 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji
AT pillarchris 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji
AT murraybev 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji
AT huganfeldavid 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji
AT shinabangerdean 1070invitroactivityofplg0206againstisolatescommonlyfoundinperiprostheticjointinfectionspji